Snapshot from Apr 17, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Innate Pharma Files 2025 Regulatory Reports
Regulatory regulatory filing

Innate Pharma Files 2025 Regulatory Reports

Analysis based on 8 articles · First reported Apr 02, 2026 · Last updated Apr 02, 2026

Sentiment
0
Attention
2
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

This event is a routine regulatory filing by Innate Pharma and is unlikely to have a significant direct impact on the broader financial markets. It primarily affects Innate Pharma by ensuring compliance with French and US financial regulations.

Biotechnology Pharmaceuticals
Event Summary

Innate Pharma announced the filing of its 2025 Universal Registration Document with the France===Autorité des marchés financiers (AMF) in France and its 2025 Form 20-F annual report with the United States===United States Securities and Exchange Commission (SEC). These filings, made on April 1, 2026, include the annual financial report, annual management report, corporate governance report, and report of Statutory Auditors. This action is part of Innate Pharma's ongoing regulatory compliance as a publicly traded biotechnology company listed on Euronext Paris and Nasdaq.

Key Actions
90 Innate Pharma filed 2025 Universal Registration Document France===Autorité des marchés financiers
90 Innate Pharma filed 2025 Form 20-F annual report United States===United States Securities and Exchange Commission
Entities Involved
stock
Innate Pharma
Innate Pharma filed its 2025 Universal Registration Document with the France===Autorité des marchés financiers (AMF) and its Form 20-F annual report with the United States===United States Securities and Exchange Commission (SEC). This is a routine regulatory compliance action.
Importance 100 Sentiment 0
govactor
France===Autorité des marchés financiers
The France===Autorité des marchés financiers is the French market authority with whom Innate Pharma filed its 2025 Universal Registration Document.
Importance 60 Sentiment 0
govactor
United States===United States Securities and Exchange Commission
The United States===United States Securities and Exchange Commission is the US regulatory body with whom Innate Pharma filed its Form 20-F annual report.
Importance 60 Sentiment 0
cnt
France
France is the country where Innate Pharma is headquartered and where the France===Autorité des marchés financiers operates.
Importance 10 Sentiment 0
cnt
United States
The United States is where Innate Pharma has a US office and where the United States===United States Securities and Exchange Commission operates.
Importance 10 Sentiment 0
stock
AstraZeneca
AstraZeneca is mentioned as a collaborator with Innate Pharma on the development of monalizumab.
Importance 5 Sentiment 0
stock
Sanofi
Sanofi is mentioned as a collaborator with Innate Pharma.
Importance 5 Sentiment 0
Relationships
Innate Pharma related ↔ France===Autorité des marchés financiers
Innate Pharma related ↔ United States===United States Securities and Exchange Commission
Innate Pharma related ↔ AstraZeneca
Innate Pharma related ↔ Sanofi
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.